Investing.com – European stock markets are expected to open in muted fashion Wednesday, with investors continuing to digest the risks associated with the Omicron Covid-19 variant heading into year-end.

Toronto-listed conglomerate gold miner, Novo Resources has kicked off ‘Phase 2’ mechanical sorter trials of bulk samples taken from its Comet Well, Purdy’s Reward, Egina and Talga Talga gold projects in the Pilbara region of WA.

ONS Director of Economic Statistics Darren Morgan said: "Our revised figures show UK GDP recovered a little slower in the third quarter, with much weaker performances from health

Western Australian Premier Mark McGowan has announced changes to the state’s vaccine mandate following Wednesday's emergency meeting of National Cabinet. The vaccine mandate – which impacts around 75 per cent of the state’s workforce – previously required people to receive two doses of a COVID-19 vaccine by the end of …

SYDNEY BUS operator Kingsford Smith Transport (KST) has been awarded a key on-demand shuttle route servicing University of Technology Sydney (UTS) students, staff and industry partners, it’s been announced. A UTS spokesperson confirmed with ABC magazine …

Greenway Health announces its Board of Directors has named Pratap Sarker as Chief Executive Officer effective January 1, 2022. Mr. Sarker,

The Bank of England has fined Metro Bank almost £5.4 million over the quality of its reporting and governance failures. The central bankPRA) watchdog confirmed it imposed the penalty on the challenger bank over failings between May 2016 and January 2019.

Tokyo stocks closed slightly higher Wednesday as overnight advances on Wall Street lifted market sentiment, while gains were limited in the downturn in trading as investors locked in profits after the stocks surged the previous day.

Li & Fung Limited (Li & Fung), the world's leading supply chain solutions partner for consumer brands and retailers, and its affiliates,

Swiss drugs giant Novartis has agreed a deal to buy a London gene therapy startup for $1.5 billion (£1.1 billion). Novartis will pay $800 million (£604 million) for Gyroscope Therapeutics now and has the potential to make additional milestone payments of up to $700 million (£528 million).